|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Allergan
|
|
gptkbp:awards
|
gptkb:Diversity_Inc_Top_50_Companies_for_Diversity
Best Places to Work
Fortune 500 company
Human Rights Campaign Corporate Equality Index score of 100
Top Employer in Europe
|
|
gptkbp:ceo
|
gptkb:Richard_A._Gonzalez
|
|
gptkbp:clinical_trial
|
Phase 1 trials for new drugs
Phase 2 trials for new drugs
Phase 3 trials for new drugs
|
|
gptkbp:employees
|
approximately 50,000
|
|
gptkbp:founded
|
gptkb:2013
|
|
gptkbp:headquarters
|
gptkb:North_Chicago,_Illinois,_USA
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Abb Vie S. A. S.
|
|
gptkbp:industry
|
gptkb:drug
|
|
gptkbp:invention
|
numerous patents in oncology
numerous patents in immunology
numerous patents in neuroscience
numerous patents in virology
|
|
gptkbp:parent_company
|
gptkb:Abb_Vie_Inc.
|
|
gptkbp:partnership
|
gptkb:healthcare_organization
gptkb:Harvard_University
gptkb:University_of_California,_San_Francisco
gptkb:University_of_Chicago
gptkb:Cleveland_Clinic
|
|
gptkbp:products
|
gptkb:Humira
gptkb:Venclexta
gptkb:Imbruvica
|
|
gptkbp:research_focus
|
oncology
neuroscience
immunology
virology
|
|
gptkbp:revenue
|
$56.1 billion (2022)
|
|
gptkbp:subsidiary
|
Abb Vie France
Abb Vie Germany
Abb Vie Japan
Abb Vie UK
|
|
gptkbp:sustainability_initiatives
|
diversity and inclusion programs
community engagement programs
environmental sustainability programs
|
|
gptkbp:symbol
|
gptkb:ABBV
|
|
gptkbp:website
|
www.abbvie.com
|
|
gptkbp:bfsParent
|
gptkb:Abb_Vie_S.r.l.
|
|
gptkbp:bfsLayer
|
4
|